期刊
HEMATOLOGY
卷 27, 期 1, 页码 609-619出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/16078454.2022.2067939
关键词
Acute myeloid leukemia; nucleophosmin 1; somatic mutation; leukemic pathogenesis; therapeutic target
类别
资金
- Huai'an City Health Scientific Research Project [HAWJ202109]
- Xuzhou Medical University [XYFM2021036]
This review discusses the mutation mechanism and therapeutic potential of nucleophosmin 1 (NPM1) in acute myeloid leukemia (AML). Dysfunctional NPM1 is suggested to cause AML by inhibiting differentiation of leukemia stem cells and acting as a protein chaperone. Besides conventional chemotherapies, NPM1 is a promising therapeutic target against AML.
Nucleophosmin 1 (NPM1, also known as B23) is a multifunctional protein involved in a variety of cellular processes, including ribosomal maturation, centrosome replication, maintenance of genomic stability, cell cycle control, and apoptosis. NPM1 is the most commonly mutated gene in adult acute myeloid leukemia (AML) and is present in approximately 40% of all AML cases. The underlying mechanisms of mutant NPM1 (NPM1(mut)) in leukemogenesis remain unclear. This review summarizes the structure and physiological function of NPM1, mechanisms underlying the pathogenesis of NPM1-mutated AML, and the potential role of NPM1 as a therapeutic target. It is reported that dysfunctional NPM1 might cause AML pathogenesis via its role as a protein chaperone, inhibiting differentiation of leukemia stem cells and regulation of non-coding RNAs. Besides conventional chemotherapies, NPM1 is a promising therapeutic target against AML that warrants further investigation. NPM1-based therapeutic strategies include inducing nucleolar relocalisation of NPM1 mutants, interfering with NPM1 oligomerization, and NPM1 as an immune response target.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据